NCT06745063 · VA Office of Research and Development
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
(EMPA)
What this study is about
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
View original scientific description
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Body mass index (BMI) 30-45 kg/m2
- 30-60 years of age at randomization
- Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030)
Exclusion criteria
- Unable to provide consent
- Diabetes mellitus
- Uncontrolled hypertension (\>180/90mmHg) or systolic \<100mmHg at screening visit
- Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
- Diagnosis of chronic kidney disease
- Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
- Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
- Use of GLP-1 analogs or SGLT2 inhibitors
- Use of hormone replacement therapy
- Use of pharmacological therapy for weight loss
- Body weight changes \>10% within the past 6 months
- History of hypersensitivity to nitrates
- History of ketoacidosis
- History of recurrent UTIs or mycotic genital infections
- Use of anticoagulants
- Change in anti-hypertensive medication regimen (if in use) during the last 90 days
Where
- Columbia, Missouri
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 14, 2025 · Source of record for eligibility and locations